Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34111952

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2021 Aug 1
First author
Richardson PG

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2021 Aug 1;39(22):2423-2425. doi: 10.1200/JCO.21.01137.
    note
    Source null
    related pmid
    34111942
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2022 Jan 1;40(1):107-108. doi: 10.1200/JCO.21.02081.
    note
    Source null
    related pmid
    34652932
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2022 Jan 1;40(1):105-106. doi: 10.1200/JCO.21.01580.
    note
    Source null
    related pmid
    34652953
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2022 Jan 1;40(1):106-107. doi: 10.1200/JCO.21.01754.
    note
    Source null
    related pmid
    34652957
    relationship
    Comment in

Authors and identifiers

  1. name
    Richardson PG
    type
    Author
  2. name
    Kumar SK
    type
    Author
  3. name
    Masszi T
    type
    Author
  4. name
    Grzasko N
    type
    Author
  5. name
    Bahlis NJ
    type
    Author
  6. name
    Hansson M
    type
    Author
  7. name
    Pour L
    type
    Author
  8. name
    Sandhu I
    type
    Author
  9. name
    Ganly P
    type
    Author
  10. name
    Baker BW
    type
    Author
  11. name
    Jackson SR
    type
    Author
  12. name
    Stoppa AM
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Richardson PG
    type
    Author
  2. name
    Kumar SK
    type
    Author
  3. name
    Masszi T
    type
    Author
  4. name
    Grzasko N
    type
    Author
  5. name
    Bahlis NJ
    type
    Author
  6. name
    Hansson M
    type
    Author
  7. name
    Pour L
    type
    Author
  8. name
    Sandhu I
    type
    Author
  9. name
    Ganly P
    type
    Author
  10. name
    Baker BW
    type
    Author
  11. name
    Jackson SR
    type
    Author
  12. name
    Stoppa AM
    type
    Author
bibliography ids
  1. nci-bib-21c959dba0f830cec40c9b54
book metadata
content sha256
190be917cdc3210d860a0fefa72cc78941fcfdd87d6459a1f01966683c499ebb
document type
citation
dois
  1. 10.1200/JCO.21.00972
electronic publication date
display
2021 Jun 11
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34111952
immutable id
pubmed:34111952@190be917cdc3210d860a0fefa72cc78941fcfdd87d6459a1f01966683c499ebb
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
22
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
2430-2442
volume
39
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2021 Aug 1;39(22):2423-2425. doi: 10.1200/JCO.21.01137.
    note
    Source null
    related pmid
    34111942
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2022 Jan 1;40(1):107-108. doi: 10.1200/JCO.21.02081.
    note
    Source null
    related pmid
    34652932
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2022 Jan 1;40(1):105-106. doi: 10.1200/JCO.21.01580.
    note
    Source null
    related pmid
    34652953
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2022 Jan 1;40(1):106-107. doi: 10.1200/JCO.21.01754.
    note
    Source null
    related pmid
    34652957
    relationship
    Comment in
outcomes validated
false
pmid
34111952
provenance
batch id
79f1021053e858d13ff3
provider
NCBI PubMed ESummary
record sha256
6a080d981aacea97f766d7973e161056210dccdee7762497a25f63786f69197d
response sha256
671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
retrieved at
2026-09-09T23:47:59.098265+00:00
publication date
display
2021 Aug 1
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34111952/
title
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Preserved source evidence · Not medical advice